Eli Lilly and AstraZeneca (AZ) have said they are to co-develop a potentially disease-modifying treatment for Alzheimer's disease (AD), in the aftermath of the high-profile failure of a Lilly ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...

New dementia diagnoses have significantly decreased since 2015, a study published in BMJ found.But more people are living ...

Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods Administration granted marketing ...

Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.

Australia’s Therapeutic Goods Administration has approved a drug called donanemab for people in the early stages of Alzheimer ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

The Therapeutic Goods Administration has approved a new drug tipped to revolutionise the treatment of hundreds of thousands ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The test potentially makes it easier to find and treat patients with the memory-robbing disease. Read more at straitstimes.com. Read more at straitstimes.com.